REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025.
Related Questions
Does the company have sufficient liquidity to fund the launch and continued pipeline development without additional financing?
What is the expected adoption rate and market penetration for VYKAT™ XR in its target rare disease indications?
Did the second quarter 2025 financial results meet or miss analyst consensus estimates?
Will the launch of VYKAT™ XR prompt an update to the company's guidance for FY2025 or FY2026 earnings and cash flow?
How does Soleno's Q2 net loss and cash runway compare to previous quarters and to peer companies in the rare‑disease space?
Are there any regulatory, reimbursement, or pricing uncertainties that could impact the commercial rollout of VYKAT™ XR?
How will the U.S. launch of VYKAT™ XR affect Soleno's Q2 and future revenue forecasts?
How does Soleno's competitive landscape look – what are rival therapies and how might they affect VYKAT™ XR's market share?
What is the anticipated impact of VYKAT™ XR on Soleno's gross margin and operating expense profile moving forward?
What are the key catalysts or risk factors in the next 12‑18 months that could drive the stock price volatility for SLNO?